Promising Peptides in Clinical Trials
The next generation of peptide medicines is being decided right now in clinical trials. Some candidates are on the verge of approval; others are early and uncertain. This guide walks through the most promising peptides in the pipeline, explains the trial stages that gate their progress, and gives an honest read of where the evidence actually stands.
Note. "In clinical trials" means a compound is still being studied and is not FDA-approved for general use. Trial status changes frequently; this article is educational, not medical advice, and is not an endorsement of using investigational compounds.
| Stage | What Happens | What It Tells You |
|---|---|---|
| Preclinical | Lab and animal studies establishing mechanism, dosing range, and basic safety. | No human data yet — the highest-uncertainty stage. |
| Phase 1 | First-in-human trials in small groups, focused on safety and tolerability. | Confirms the compound is safe enough to study further. |
| Phase 2 | Mid-size trials testing whether the drug actually works and at what dose. | The first real efficacy signal in patients. |
| Phase 3 | Large, often multi-thousand-patient trials confirming benefit vs existing options. | The data the FDA relies on for approval. |
A triple agonist hitting the GLP-1, GIP, and glucagon receptors. Phase 2 data showed some of the largest weight reductions ever recorded for a metabolic drug, and it is now in late-stage trials.
Why it matters: If the Phase 3 results hold, retatrutide could set a new ceiling for pharmacological weight loss.
A long-acting amylin analogue, studied both alone and combined with semaglutide (the 'CagriSema' combination). Targets appetite and satiety through a pathway distinct from GLP-1.
Why it matters: Combining complementary mechanisms may push efficacy beyond what GLP-1 alone achieves.
Survodutide
A GLP-1 / glucagon dual agonist being developed for both obesity and metabolic-associated steatohepatitis (fatty liver disease), an area with very few approved options.
Why it matters: A genuine unmet need — effective MASH therapies are scarce.
Mazdutide
A GLP-1 / glucagon dual agonist peptide in late-stage development, designed to drive weight loss while improving liver and lipid markers through the glucagon arm.
Why it matters: Adds glucagon-driven energy expenditure on top of GLP-1 appetite control.
One of the most discussed research peptides for healing and gut health. Despite extensive animal data and strong anecdotal interest, rigorous large-scale human trials remain limited.
Why it matters: Huge popular interest, but the controlled human evidence base is still thin.
An immune-modulating peptide approved in several countries and studied across infection and oncology settings; still working toward broader regulatory acceptance.
Why it matters: A rare research peptide with substantial clinical study behind it.
Pemvidutide
Another GLP-1 / glucagon dual agonist in development for weight loss and liver disease, designed to drive fat loss while preserving lean mass.
Why it matters: Body-composition quality is becoming a key differentiator in this class.
The success of GLP-1 drugs reshaped the entire field. After semaglutide and tirzepatide proved that gut-hormone agonists could deliver dramatic, durable weight loss, virtually every major developer pivoted toward multi-receptor incretin peptides. That is why the late-stage pipeline is crowded with triple agonists, amylin analogues, and glucagon co-agonists.
The emerging theme is not just how much weight comes off, but the quality of the loss — preserving lean mass, improving liver and cardiovascular markers, and tackling adjacent conditions like fatty liver disease. To understand the underlying biology, see how GLP-1 works for weight loss.
Promising is not the same as proven. Many compounds with exciting Phase 2 data never make it through Phase 3 — efficacy fades, side effects emerge, or the benefit simply does not beat existing options. A peptide "in trials" has, by definition, not yet cleared the bar that separates investigational compounds from approved medicines.
This matters especially for popular research peptides like BPC-157, where online enthusiasm has run far ahead of the controlled human evidence. Once a compound is approved, it moves to our FDA-approved peptides list. Until then, treat trial-stage data as a signal, not a guarantee — and read do peptides actually work? for how to weigh the evidence.
Peptide Detail Profiles
Related Guides
Other Articles
Calculator
Calculate exact reconstitution volumes and insulin unit doses for any peptide protocol.
Open Calculator →